Literature DB >> 1753390

Contact-haemolysin production by entero-invasive Escherichia coli and shigellae.

K Haider1, M J Albert, A Hossain, S Nahar.   

Abstract

Entero-invasive Escherichia coli (EIEC) and shigellae were tested for contact-haemolysin (CH) with red blood cells (RBCs) of guinea-pig, rabbit, rat, mouse, monkey, man, sheep and chicken; all bacteria showed the best lysis with guinea-pig RBCs. The best culture medium for CH activity of shigellae was tryptic soy broth, and for EIEC it was casamino acid-yeast extract broth with 1 mM CaCl2. CH production by all species was best at the slightly alkaline pH which is optimal for growth; it was also dependent on the presence of a large (140-Mda) plasmid. Pre-treatment of bacteria with homologous antisera inhibited CH activity. Various treatments of bacterial cells and RBCs suggested that CH may be a protein molecule, and that a chitotriose-like moiety may serve as CH receptor. RBCs that were incubated with bacteria at 4 degrees C, or with heat-killed bacteria at 37 degrees C, were not lysed; also, isolated cell-surface components (lipopolysaccharide and outer-membrane protein) did not lyse RBCs. This suggests that metabolically active cells are required for CH activity. Production of CH by both EIEC and shigellae is consistent with a common mechanism for the virulence of these organisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1753390     DOI: 10.1099/00222615-35-6-330

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  2 in total

1.  Contact hemolysin production by strains of enteroaggregative Escherichia coli isolated from children with diarrhea.

Authors:  M A Haque; K Ohki; M Kikuchi; O Kohashi
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

2.  In vivo hemolytic activity of group B streptococcus is dependent on erythrocyte-bacteria contact and independent of a carrier molecule.

Authors:  M W Platt
Journal:  Curr Microbiol       Date:  1995-07       Impact factor: 2.188

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.